Prediction and prevention of type 1 diabetes: Update on success of prediction and struggles at prevention

Pediatric Diabetes

Volumn 16, Issue 7, 2015, Pages 465-484

  Michels, Aaron ^a   Zhang, Li ^a   Khadra, Anmar ^b   Kushner, Jake A ^c   Redondo, Maria J ^c   Pietropaolo, Massimo ^d  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoantibodies; Diabetes; Prediction of type 1 diabetes; Prevention of type 1; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUTAMATE DECARBOXYLASE; HLA ANTIGEN; HLA DQ ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G1; PROTEIN TYROSINE PHOSPHATASE; SOTAGLIFLOZIN; ZINC TRANSPORTER; BIOLOGICAL MARKER;

ALLELE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE LOCUS; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOZYGOTIC TWINS; PANCREAS ISLET BETA CELL; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; T CELL LYMPHOMA; ANIMAL; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; BIOLOGICAL MODEL; BLOOD; CD4+ T LYMPHOCYTE; CHILD; DIABETES MELLITUS, TYPE 1; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; INFANT; METABOLISM; MULTIFACTORIAL INHERITANCE; PANCREAS ISLET; PATHOPHYSIOLOGY; PEDIATRICS; PREDIABETIC STATE; PRESCHOOL CHILD; PROCEDURES; TRENDS;

ANIMALS; ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INFANT; ISLETS OF LANGERHANS; MODELS, IMMUNOLOGICAL; MULTIFACTORIAL INHERITANCE; PEDIATRICS; POLYMORPHISM, GENETIC; PREDIABETIC STATE;

EID: 84942988736     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12299     Document Type: Review

References (183)

1. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986: 314: 1360-1368.
2. Todd JA, Bell JI, McDevitt HO. HLA-DQ-gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987: 329: 599-604.
3. Morel PA, Dorman JS, Todd JA, McDevitt HO, Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. Proc Natl Acad Sci USA 1988: 85: 8111-8115.
4. Lonnrot M, Korpela K, Knip M et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 2000: 8: 1314-1318.
5. Orchard TJ, Forman JS, LaPorte RE, Ferrell RE, Drash AL. Host and environmental interactions in diabetes mellitus. J Chronic Dis 1986: 979-999.
6. Zipris D, Lien E, Nair A et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol 2007: 2: 693-701.
7. Hyoty H. Enterovirus infections and type 1 diabetes. Ann Med 2002: 3: 138-147.
8. Jaberi-Douraki M, Schnell S, Pietropaolo M, Khadra A. Unraveling the contribution of pancreatic beta-cell suicide in autoimmune type 1 diabetes. J Theor Biol 2014.
9. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004: 20: 2068-2079.
10. Pitkänen J, Peterson P. Autoimmune regulator: from loss of function to autoimmunity. Genes Immun 2003: 1: 12-21.
11. Husebye ES, Anderson MS. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity 2010: 4: 479-487.
12. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003: 5609: 1057-1061.
13. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008: 5899: 271-275.
14. Flanagan SE, Haapaniemi E, Russell MA et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014: 8: 812-814.
15. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974: 2: 1279-1282.
16. Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983: 222: 1337-1339.
17. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001: 9277: 221-229.
18. Pietropaolo M, Eisenbarth GS. Autoantibodies in human diabetes. Curr Dir Autoimmun 2001: 4: 252-282.
19. Bonifacio E, Yu L, Williams AK et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 2010: 7: 3360-3367.
20. Morran MP, Casu A, Arena VC et al. Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of type 1 diabetes. Endocrinology 2010: 6: 2528-2537.
21. Ziegler AG, Rewers M, Simell O et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013: 23: 2473-2479.
22. LaPorte RE, Matsushima M, and Chang YF.
23. Parkkola A, Härkönen T, Ryhänen S, Ilonen J, Knip M, and the Finnish Pediatric Diabetes Register. Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children. Diabetes Care 2013: 36: 348-354.
24. Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in type I diabetes and associated disorders. Diabetologia 2002: 45: 605-622.
25. Kaprio J, Tuomilehto J, Koskenvuo M et al. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992: 35:1060-1067.
26. Redondo MJ, Jeffrey J, Fain PR, Eisenbarth GS, Orban T. Concordance for islet autoimmunity among monozygotic twins. N Engl J Med 2008: 26: 2849-2850.
27. Gale EA, Bingley PJ, Eisenbarth GS, Redondo MJ, Kyvik KO, Petersen JS. Reanalysis of twin studies suggests that diabetes is mainly genetic. BMJ 2001: 7319: 997-998.
28. Redondo MJ, Fain PR, Krischer JP et al. Expression of beta-cell autoimmunity does not differ between potential dizygotic twins and siblings of patients with type 1 diabetes. J Autoimmun 2004: 3: 275-279.
29. Aly TA, Ide A, Jahromi MM et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci USA 2006: 38: 14074-14079.
30. Turner A. Up hill and down dale in the genomic landscape: the odd distribution of matching segments. J Genet Geneal 2010: 1: 4.
31. Elding Larsson H, Larsson C, Lernmark Å. Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention. Acta Diabetol 2014.
32. Althof N, Whitton JL. Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors. J Virol 2013: 5: 2823-2834.
33. Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med 1997: 3: 517-530.
34. Alexander WJ, Holmes JR, Shaw JF, Riley WE, Roper WL. Norwalk virus outbreak at a college campus. South Med J 1986: 79: 33-36, 40.
35. Trucco M, LaPorte R. Exposure to superantigens as an immunogenetic explanation of type I diabetes mini-epidemics. J Pediatr Endocrinol 1995: 8: 3-10.
36. Roivainen M, Rasilainen S, Ylipaasto P et al. Mechanisms of coxsackievirus-induced damage to human pancreatic beta-cells. J Clin Endocrinol Metab 2000: 1: 432-440.
37. Sestak K, Feely S, Fey B et al. Experimental inoculation of juvenile rhesus macaques with primate enteric caliciviruses. PLoS One 2012: 5: e37973.
38. Simonen-Tikka ML, Klemola P, Suomenrinne S et al. Virus infections among young children - the first year of the INDIS study. J Med Virol 2013: 9: 1678-1684.
39. Savolainen-Kopra C, Simonen-Tikka ML, Klemola P et al. Human rhinoviruses in INDIS-study material-evidence for recovery of viable rhinovirus from fecal specimens. J Med Virol 2013: 8: 1466-1472.
40. Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc Natl Acad Sci USA 2013: 50: 20236-20241.
41. Nielsen DS, Krych L, Buschard K, Hansen CH, Hansen AK. Beyond genetics. Influence of dietary factors and gut microbiota on type 1 diabetes. FEBS Lett 2014: 22: 4234-4243.
42. Kuss SK, Best GT, Etheredge CA et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011: 6053: 249-252.
43. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008: 7216: 1109-1113.
44. Hara N, Alkanani AK, Ir D et al. Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol 2012: 8: 3805-3814.
45. Brown CT, Davis-Richardson AG, Giongo A et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011: 10: e25792.
46. Murri M, Leiva I, Gomez-Zumaquero JM et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 2013: 11: 46.
47. Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med 2015: 42: 42-60
48. Todd JA, Acha-Orbea H, Bell JI et al. A molecular basis for MHC class II associated autoimmunity. Science 1988: 240: 1003-1009.
49. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996: 85: 291-297.
50. Rowe RE, Leech NJ, Nepom GT, McCulloch DK. High genetic risk for IDDM in the Pacific Northwest: first report from the Washington State diabetes prediction study. Diabetes 1994: 43: 87-94.
51. Barker JM, Barriga KJ, Yu L et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004: 8: 3896-3902.
52. Undlien DE, Friede T, Rammensee HG et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997: 1: 143-149.
53. Baschal EE, Aly TA, Babu SR et al. HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 2007: 9: 2405-2409.
54. Pietropaolo M, Becker DJ, LaPorte RE et al. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high risk haplotypes. Diabetologia 2002: 45: 66-76.
55. Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP. Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. J Clin Endocrinol Metab 2000: 3: 1255-1260.
56. Pugliese A, Gianani R, Moromisato R et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody positive first degree relatives of patients with insulin-dependent diabetes. Diabetes 1995: 44: 608-613.
57. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007: 7: 857-864.
58. Rich SS, Akolkar B, Concannon P et al. Current status and the future for the genetics of type I diabetes. Genes Immun 2009: Suppl 1: S128-S131.
59. Howson JM, Cooper JD, Smyth DJ et al. Evidence of gene-gene interaction and age-at-diagnosis effects in type 1 diabetes. Diabetes 2012: 11: 3012-3017.
60. Nistico L, Buzzetti R, Pritchard LE et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet 1996: 7: 1075-1080.
61. Bottini N, Musumeci L, Alonso A et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004: 4: 337-338.
62. Barrett JC, Clayton DG, Concannon P et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009: 6: 703-707.
63. Bell GI, Karam JH, Rutter WJ. Polymorphic DNA region adjacent to the 5' end of the human insulin gene. Proc Natl Acad Sci USA 1981: 78: 5759-5763.
64. Rotwein PS, Chirgwin J, Province M, Knowler WC, Pettitt DJ, Cordell B, Goodman HM, Permutt MA. Polymorphism in the 5′ flanking region of the human insulin gene: a genetic marker for non-insulin-dependent diabetes. N Engl J Med 1983: 308: 65-71.
65. Owerbach D, Nerup J. Restriction fragment length polymorphism of the insulin gene in diabetes mellitus. Diabetes 1982: 31: 275-277.
66. Julier C, Hyer RN, Davies J et al. Insulin-IGF2 region encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature 1991: 354: 155-159.
67. Bain SC, Prins JB, Hearne CM et al. Insulin gene region-encoded susceptibility to type I diabetes is not restricted to HLA-DR4-positive individuals. Nat Genet 1992: 2: 212-215.
68. Lucassen AM, Screaton GR, Julier C, Elliot TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet 1994: 4: 501-506.
69. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet 1995: 9: 293-298.
70. Bennett ST, Lucassen AM, Gough SCL et al. Susceptibility to human type I diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995: 9: 284-292.
71. Pugliese A, Zeller M, Fernandez JrA et al. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997: 15: 293-297.
72. Nakayama M, Abiru N, Moriyama H et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005: 7039: 220-223.
73. Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trucco M. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 2009: 18: 2812-2824.
74. Durinovic-Bello I, Gersuk VH, Ni C et al. Avidity-dependent programming of autoreactive T cells in T1D. PLoS One 2014: 5: e98074.
75. Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006: 4: 207-213.
76. Vang T, Congia M, Macis MD et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005: 12: 1317-1319.
77. Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2005: 1: 3-16.
78. Marron MP, Raffel LJ, Garchon HJ et al. Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet 1997: 8: 1275-1282.
79. Verge CF, Gianani R, Kawasaki E et al. Prediction of type I diabetes mellitus in first degree relatives using a combination of insulin, glutamic acid decarboxylase and ICA512bdc/IA-2 autoantibodies. Diabetes 1996: 45: 926-933.
80. Wenzlau JM, Juhl K, Yu L et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007: 43: 17040-17045.
81. Pietropaolo M, Towns R, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med 2012: 2: pii: a012831.
82. Pietropaolo M, Castaño L, Babu S et al. Islet cell autoantigen 69 kDa (ICA69): molecular cloning and characterization of a novel diabetes associated autoantigen. J Clin Invest 1993: 92: 359-371.
83. Fan Y, Gualtierotti G, Tajima A et al. Compromised central tolerance of ICA69 induces multiple organ autoimmunity. J Autoimmun 2014: 53: 10-25.
84. Jarchum I, Nichol L, Trucco M, Santamaria P, DiLorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin Immunol 2008: 3: 359-365.
85. Stadinski BD, Delong T, Reisdorph N et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010: 3: 225-231.
86. Bach J-F, Chatenaud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001: 19: 131-161.
87. Boitard C, Villa MC, Becourt C et al. Peripherin: an islet antigen that is cross-reactive with nonobese diabetic mouse class II gene products. Proc Natl Acad Sci USA 1992: 89: 172-176.
88. Winer S, Tsui H, Lau A et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003: 9: 198-205.
89. Eggleton P, Haigh R, Winyard PG. Consequence of neo-antigenicity of the 'altered self'. Rheumatology (Oxford) 2008: 5: 567-571.
90. Doyle HA, Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 2012: 1: 112-118.
91. Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004: 3: 185-188.
92. Moscarello MA, Mastronardi FG, Wood DD. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007: 2: 251-256.
93. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001: 6: 4177-4184.
94. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004: 9: 1085-1089.
95. Yu L, Robles DT, Abiru N, Rewers M, Kelemen K, Eisenbarth GS. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci USA 2000: 4: 1701-1706.
96. Crawford F, Stadinski B, Jin N et al. Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci USA 2011: 40: 16729-16734.
97. Alleva DG, Crowe PD, Jin L et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001: 2: 173-180.
98. Arif S, Tree TI, Astill TP et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004: 3: 451-463.
99. Kent SC, Chen Y, Bregoli L et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005: 7039: 224-228.
100. Pathiraja V, Kuehlich JP, Campbell PD et al. Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes. Diabetes 2015: 1: 172-182.
101. Baekkeskov S, Warnock G, Christie M, Rajotte RV, Larsen PM, Fey S. Revelation of specificity of 64 K autoantibodies in IDDM serums by high-resolution 2-D gel electrophoresis: unambiguous identification of 64 K target antigen. Diabetes 1989: 38: 1133-1141.
102. Solimena M, Folli F, Denis-Donini S et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiffman syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988: 318: 1012-1020.
103. Baekkeskov S, Aanstoot H, Christgau S et al. Identification of the 64 K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990: 347: 151-156.
104. Atkinson MA, Kaufman DL, Newman D, Tobin AJ, Maclaren NK. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. J Clin Invest 1993: 91: 350-356.
105. Karlsen AE, Hagopian WA, Grubin CE et al. Cloning and primary structure of a human isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci USA 1991: 88: 8337-8341.
106. Hagopian WA, Michelsen B, Karlsen AE et al. Autoantibodies in IDDM primarily recognize the 65, 000-Mr rather than the 67, 000-Mr isoform of glutamic acid decarboxylase. Diabetes 1993: 42: 631-636.
107. Lan MS, Lu J, Goto Y, Notkins AL. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994: 13: 505-514.
108. Achenbach P, Warncke K, Reiter J et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004: 2: 384-392.
109. Wasmeier C, Hutton JC. Molecular cloning of phogrin, a protein tyrosyne phosphatase homologue localized to insulin secretory granule membranes. J Biol Chem 1996: 30: 18161-18170.
110. Mziaut H, Trajkovski M, Kersting S et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 2006: 5: 435-445.
111. Kawasaki E, Yu L, Gianani R et al. Evaluation of islet cell antigen (ICA) 512/IA-2 autoantibody radioassay using overlapping ICA512/IA-2 constructs. J Clin Endocrinol Metab 1997: 82: 375-380.
112. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004: 9: 2330-2337.
113. Wijesekara N, Chimienti F, Wheeler MB. Zinc, a regulator of islet function and glucose homeostasis. Diabetes Obes Metab 2009: 11 Suppl 4: 202-214.
114. Wijesekara N, Dai FF, Hardy AB et al. Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. Diabetologia 2010: 8: 1656-1668.
115. Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW. Identification of a major humoral epitope in Slc30A8 (ZnT8). Ann N Y Acad Sci 2008: 1150: 252-255.
116. Yu L, Liu Y, Miao D et al. Triple chimeric islet autoantigen IA2-ZnT8WR to facilitate islet autoantibody determination. J Immunol Methods 2010: 1-2: 20-23.
117. Gottlieb PA, Delong T, Baker RL et al. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun 2014: 50: 38-41.
118. Xu P, Wu Y, Zhu Y et al. Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes. Diabetes Care 2010: 12: 2508-2513.
119. Steck AK, Johnson K, Barriga KJ et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011: 6: 1397-1399.
120. Eisenbarth GS, Gianani R, Yu L et al. Dual-parameter model for prediction of type I diabetes mellitus. Proc Assoc Am Physicians 1998: 2: 126-135.
121. Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009: 12: 2269-2274.
122. Pietropaolo M, Yu S, Libman IM et al. Cytoplasmic islet cell antibodies remain valuable in defining risk of progression to type 1 diabetes in subjects with other islet autoantibodies. Pediatr Diabetes 2005: 4: 184-192.
123. Andersson C, Kolmodin M, Ivarsson SA et al. Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitus negative for other islet cell antibodies. Pediatr Diabetes 2014: 5: 336-344.
124. Ilonen J, Hammais A, Laine AP et al. Patterns of beta-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 2013: 10: 3636-3640.
125. Herold KC, Hagopian W, Auger JA et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002: 22: 1692-1698.
126. Hagopian W, Ferry RJ Jr, Sherry N et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 2013: 11: 3901-3908.
127. Gitelman SE, Gottlieb PA, Rigby MR et al. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2013: 4: 306-316.
128. Rigby MR, DiMeglio LA, Rendell MS et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013: 4: 284-294.
129. Haller MJ, Gitelman SE, Gottlieb PA et al. Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest 2015: 1: 448-455.
130. Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am 2014: 4: 797-811.
131. The DIAMOND, Group Project. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006: 23: 857-866.
132. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009: 9680: 2027-2033.
133. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008: 9626: 1777-1782.
134. Barker JM, Goehrig SH, Barriga K et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care 2004: 6: 1399-1404.
135. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012: 1: 179-186.
136. Miao D, Guyer KM, Dong F et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013: 12: 4174-4178.
137. Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013: 8: 2266-2270.
138. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004: 10: 1661-1667.
139. Hirata S, Tanaka Y. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. Expert Rev Clin Pharmacol 2015: 1: 115-122.
140. Knip M, Virtanen SM, Seppa K et al. Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 2010: 20: 1900-1908.
141. Knip M, Akerblom HK, Becker D et al. Hydrolyzed infant formula and early beta-cell autoimmunity: a randomized clinical trial. JAMA 2014: 22: 2279-2287.
142. Hummel S, Pfluger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care 2011: 6: 1301-1305.
143. Sorensen IM, Joner G, Jenum PA, Eskild A, Torjesen PA, Stene LC. Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. Diabetes 2012: 1: 175-178.
144. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001: 9292: 1500-1503.
145. Pugliese A. The multiple origins of type 1 diabetes. Diabet Med 2013: 2: 135-146.
146. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002: 22: 1685-1691.
147. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial - type 1. Diabetes Care 2005: 5: 1068-1076.
148. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011: 7: 1585-1590.
149. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004: 9413: 925-931.
150. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005: 25: 2598-2608.
151. Stumpf M, Zhou X, Bluestone JA. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol 2013: 3: 961-969.
152. Orban T, Bundy B, Becker DJ et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014: 4: 1069-1075.
153. Redondo MJ, Yu L, Hawa M et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001: 3: 354-362.
154. Redondo MJ, Rodriguez LM, Escalante M, O'Brian SE, Balasubramanyam A, Haymond MW. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes 2012: 7: 564-571.
155. Redondo MJ, Rodriguez LM, Escalante M, Smith EO, Balasubramanyam A, Haymond MW. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis. Pediatr Diabetes 2013: 5: 333-340.
156. Redondo MJ, Muniz J, Rodriguez LM et al. Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes. BMJ Open Diabetes Res Care 2014: 1: e000008.
157. Yang Y, Santamaria P. Lessons on autoimmune diabetes from animal models. Clin Sci (Lond) 2006: 6: 627-639.
158. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014: 9911: 69-82.
159. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med 2013: 3: pii: a015552.
160. Grinberg-Bleyer Y, Baeyens A, You S et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010: 9: 1871-1878.
161. Rosenzwajg M, Churlaud G, Mallone R et al. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun 2015: 58: 48-58.
162. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015: 2: 101-110.
163. D'Amour KA, Bang AG, Eliazer S et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006: 11: 1392-1401.
164. Pagliuca FW, Millman JR, Gurtler M et al. Generation of functional human pancreatic beta cells in vitro. Cell 2014: 2: 428-439.
165. Fox IJ, Daley GQ, Goldman SA, Huard J, Kamp TJ, Trucco M. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science 2014: 345: 1247391.
166. Rezania A, Bruin JE, Arora P et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014: 11: 1121-1133.
167. Di CV, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One 2014: 1: e83575.
168. Michels AW, Nakayama M. The anti-insulin trimolecular complex in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2010: 4: 329-334.
169. Michels AW. Targeting the trimolecular complex. Clin Immunol 2013: 3: 339-344.
170. Michels AW. Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention. Diabetes Technol Ther 2013: 15 Suppl 2: S2-8-S2-12.
171. Eisenbarth GS. Banting Lecture 2009: an unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010: 59: 759-774.
172. Erlich H, Valdes AM, Noble J et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabetes 2008.
173. Michels AW, Ostrov DA, Zhang L et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol 2011: 11: 5921-5930.
174. Yang J, Chow IT, Sosinowski T et al. Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. Proc Natl Acad Sci USA 2014: 41: 14840-14845.
175. Nakayama M, McDaniel K, Fitzgerald-Miller L et al. Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects. Proc Natl Acad Sci USA 2015: 14: 4429-4434.
176. Daniel C, Weigmann B, Bronson R, von BH. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong agonist insulin mimetope. J Exp Med 2011: 7: 1501-1510.
177. Zhang L, Stadinski BD, Michels A, Kappler JW, Eisenbarth GS. Immunization with an insulin peptide-MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metab Res Rev 2011: 8: 784-789.
178. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth GS, Kappler JW. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci USA 2010: 24: 10978-10983.
179. Zhang L, Crawford F, Yu L et al. Monoclonal antibody blocking the recognition of an insulin peptide-MHC complex modulates type 1 diabetes. Proc Natl Acad Sci USA 2014: 7: 2656-2661.
180. Zhang L, Jasinski JM, Kobayashi M et al. Analysis of T cell receptor beta chains that combine with dominant conserved TRAV5D-4*04 anti-insulin B:9-23 alpha chains. J Autoimmun 2009: 1: 42-49.
181. Nakayama M, Castoe T, Sosinowski T et al. Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice. Diabetes 2012: 4: 857-865.
182. Liu Z, Cort L, Eberwine R et al. Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: Vbeta13 as a therapeutic target and biomarker. Diabetes 2012: 5: 1160-1168.
183. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008: 223:371-390.